Medical Condition News

RSS

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

An old pinworm medicine is a new lead in the search for compounds that block a signaling pathway implicated in colon cancer. The findings, reported by Vanderbilt University Medical Center researchers in the November issue of Nature Chemical Biology, suggest a fresh approach for developing therapeutics that target the pathway.

20 Nov 2010

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.

20 Nov 2010

Consuming a variety of fruit reduces lung cancer risk by 23%

Eating five portions of fruit and vegetables per day is one of the means that experts most frequently recommend for preventing cancer. Now, the European EPIC study carried out by researchers from 10 countries has shown that, in the case of lung cancer, the important thing is not just the quantity but also the variety of fruit consumed, which can reduce the risk by up to 23%.

20 Nov 2010

Medtronic's Valiant Stent System effective for thoracic aortic aneurysms treatment

An implantable medical device used in the minimally invasive treatment of thoracic aortic aneurysms, the Valiant Thoracic Stent Graft System from Medtronic, Inc., delivered strong results through 30 days of patient follow-up in the company's U.S. pivotal study, according to clinical data presented at VEITHsymposium.

19 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.

From Baxter International Inc. 19 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.

19 Nov 2010

Task Force for National Conference on Diabetes issues Call to Action to improve diabetes care

The Task Force for the National Conference on Diabetes issued a Call to Action today entitled Shaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact. This Call to Action is a result of the National Conference on Diabetes, held earlier this year in Washington, D.C., which was attended by nearly 100 participants representing the Administration, Congress, government officials, public health organizations and industry.

19 Nov 2010

Boston Scientific's CRT-Ds, ICDs receive CE Mark approval

Boston Scientific Corporation today announced CE Mark approval of its INCEPTA, ENERGEN and PUNCTUA cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators.

19 Nov 2010

Substance abuse treatment facilities offering nicotine replacement therapy increased by 6%: Report

The percentage of substance abuse treatment facilities offering nicotine replacement therapy to clients gradually increased by about 6 percentage points from 2006 to 2009, according to a new Spotlight report issued by the Substance Abuse and Mental Health Services Administration released in conjunction with the "Great American Smokeout."

19 Nov 2010

SAMHSA: 4.8% U.S. adults suffer from serious mental illness

According to new results from a national survey, 19.9 percent of American adults in the United States (45.1 million) have experienced mental illness over the past year. The survey conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA) indicates that 11 million adults (4.8 percent) in the U.S. suffered serious mental illness in the past year a diagnosable mental disorder has substantially interfered with, or limited one or more major life activities.

19 Nov 2010

ENERCA network organizes European Symposium on rare anemias

It is estimated that rare diseases -those whose frequency is under 5 cases / 10,000 people- affect about 6% of the European population. In the field of anemia, 1% of couples are at risk of having a newborn with a severe syndrome of hemoglobin. More than 330,000 children are born worldwide each year affected by one of these diseases, being the most common disorders sickle cell anemia and thalassemia syndromes.

19 Nov 2010

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.

19 Nov 2010

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Physical activity may protect high-risk individuals from cognitive decline: Study

Physical activity promotes changes in the brain that may protect high-risk individuals against cognitive decline, including development of Alzheimer's disease, according to a new study done at the University of Wisconsin-Milwaukee (UWM).

19 Nov 2010

Research suggests new therapeutic approach to prevent transplant rejection

UCLA researchers have pinpointed the culprit behind chronic rejection of heart, lung and kidney transplants. Published in the Nov. 23 edition of Science Signaling, their findings suggest new therapeutic approaches for preventing transplant rejection and sabotaging cancer growth.

19 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

Medical Condition News

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Consuming a variety of fruit reduces lung cancer risk by 23%

Medtronic's Valiant Stent System effective for thoracic aortic aneurysms treatment

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Task Force for National Conference on Diabetes issues Call to Action to improve diabetes care

Boston Scientific's CRT-Ds, ICDs receive CE Mark approval

Substance abuse treatment facilities offering nicotine replacement therapy increased by 6%: Report

SAMHSA: 4.8% U.S. adults suffer from serious mental illness

ENERCA network organizes European Symposium on rare anemias

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Physical activity may protect high-risk individuals from cognitive decline: Study

Research suggests new therapeutic approach to prevent transplant rejection

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News